Physiatry-Led Cancer Prehabilitation During Neoadjuvant Systemic Therapy to Improve Function in Stage III-IVA Gynecologic Cancer Patients

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCity of Hope Medical Center

About this trial

This clinical trial studies whether physiatry-led cancer prehabilitation can be used during systemic treatment before surgery (neoadjuvant systemic treatment \[NST\]) to improve function in stage III-IVA gynecologic cancer patients. Treatment of gynecologic cancers presents significant challenges to physical and mental health and patients often experience many challenges following treatment including sleep disturbance, extreme tiredness, sexual dysfunction, and bowel and urinary problems. Patients who have low functioning prior to surgery often have worse outcomes following surgery; however, services to support functional shortages often start after surgery. Physiatry-led cancer prehabilitation is a strategy aimed at reducing post-treatment functional challenges by improving physical and mental function before treatment. It involves physiatry, which is a medical specialty focused on function. Physiatry involvement in prehabilitation allows for the evaluation and management of co-existing conditions, medical supervision, and the coordination of complex plans involving multiple teams. Using physiatry-led cancer prehabilitation during NST may be an effective way to improve function in stage III-IVA gynecologic cancer patients.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

PATIENT: Documented informed consent of the participant

PATIENT: Willingness to comply with a physiatry consultation, start a tailored training program, and follow-up assessments

PATIENT: Age: ≥ 18 years

PATIENT: Able to read and write in English

Disqualifiers

PATIENT: Current or planned cancer treatment for a second cancer

PATIENT: Clinically significant uncontrolled illness limiting participation with the research intervention and assessments

PATIENT: Stage IVB cancer with distant metastases

PATIENT: Other active malignancy

Trial design

Design model

Single group

Treatments tested in this trial

  • Educational Intervention

    Other intervention

    Receive written prehabilitation education materials

  • Goal Setting

    Other intervention

    Follow and meet prehabilitation goals

  • Interview

    Other intervention

    Ancillary studies

  • Referral

    Other intervention

    Receive tailored multidisciplinary referrals

  • Rehabilitation

    Procedure/Surgery

    Attend cancer physiatry consultation

  • Supportive Care

    Other intervention

    Receive resistance bands, nutritional guidance sources, and tips and resources

  • Survey Administration

    Other intervention

    Ancillary studies

  • Tailored Intervention

    Procedure/Surgery

    Receive starter prescription

Treatment groups

25 Participants
are divided into 1 treatment group
Group A: Supportive care (physiatry-led prehabilitation)Experimental treatment 8 interventions

Trial outcomes

Primary outcomes

1

Participant completion and adherence to the prescribed training program (Feasibility)

Feasibility will be determined primarily by participant adherence to the prescribed training program during the 28-day period immediately prior to surgery, with the goal of \> 70% adherence across each key category-exercise (aerobic and resistance), nutrition, and mind/spirit practice-in \> 70% of enrolled patients. Adherence will be measured via a self-reported weekly training log that will be turned in routinely to the clinical research staff. Feasibility assessment will include descriptive statistics such as frequencies (%), along with estimates of precision (95% confidence intervals).

Time frame
Up to 28 days immediately prior to surgery

Secondary outcomes

1

Enrollment rate (Feasibility)

Secondarily, feasibility will be evaluated via enrollment rate \> 50% of eligible patients. Feasibility assessment will include descriptive statistics such as frequencies (%), along with estimates of precision (95% confidence intervals).

Time frame
Up to 1 year
2

Change in physical measures - Six Minute Walk Test (6MWT)

This Six Minute Walk Test (6MWT) test measures the distance a patient walks in 6 minutes. Changes in the outcome measure will be analyzed using paired t-tests (or non-parametric tests if the data distributions deviate from normality). These analyses will be intended to provide preliminary estimates and effect sizes, which will inform the design of future studies. The main objective will be to detect a signal rather than to test a formal hypothesis.

Time frame
From Baseline up to 21-35 days post-surgery
3

Change in physical measures - Duke Activity Status Index (DASI)

This is a 12-question validated patient-reported outcome measure of self-reported functional capacity. Changes in the outcome measure will be analyzed using paired t-tests (or non-parametric tests if the data distributions deviate from normality). These analyses will be intended to provide preliminary estimates and effect sizes, which will inform the design of future studies. The main objective will be to detect a signal rather than to test a formal hypothesis.

Time frame
From Baseline up to 21-35 days post-surgery
4

Change in physical measures - 30-second Sit to Stand (30STS)

This is an objective measure of functional capacity and lower body functional strength assessing how many times a person can go from sitting to standing within 30 seconds. Changes in the outcome measure will be analyzed using paired t-tests (or non-parametric tests if the data distributions deviate from normality). These analyses will be intended to provide preliminary estimates and effect sizes, which will inform the design of future studies. The main objective will be to detect a signal rather than to test a formal hypothesis.

Time frame
From Baseline up to 21-35 days post-surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

City of Hope Medical Center

Lead sponsor

National Cancer Institute (NCI)

Collaborator

This trial is not recruiting at the moment. You can still explore other options: